The company will use the equity financing "to continue in-licensing and developing a ... pipeline of late-stage drugs, exploiting Perlegen's ability to target the right drugs to the right patients," Robert Middlebrook, chief corporate development officer of Perlegen, said in a statement.
CSK Venture Capital led the financing, followed by new investors Brookside Capital, an affiliate of Bain Capital; Mizuho Securities; Glynn Capital Management;
Previous investors also participating in the financing included Affymetrix, Alex Zaffaroni, Maverick Capital, Lombard Odier Darier Hentsch & Cie, Zesiger Capital, Sano Ventures, BSI SA, MPM BioEquities, SB Life Sciences, Unilever Ventures, Biofrontier Partners, Private Life Biomed, and CMEA Ventures.